The next step was to combine HIV infection of resting CD4+ T cells with CRISPR gene editing and test the latency reversal potential of TRAF2 and UHRF1 directly in primary resting CD4+ T cells. This evidence concerns the gene TRAF2 and HIV infectious disease.